Predicting severity of acute pancreatitis

被引：46

作者：

Rau B.M. ^{[1
]}

机构：

[1] Department of General, Visceral, and Vascular Surgery, University of the Saarland, 66421 Homburg, Saar, Kirrberger Strasse

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 2期

关键词：

Acute Pancreatitis; Organ Failure; Severe Acute Pancreatitis; Procalcitonin; Activation Peptide;

D O I：

10.1007/s11894-007-0004-5

中图分类号：

学科分类号：

摘要：

Severity stratification is a critical issue in acute pancreatitis that strongly influences diagnostic and therapeutic decision making. According to the widely used Atlanta classification, "severe" disease comprises various local and systemic complications that are associated with an increased risk of mortality. However, results from recent clinical studies indicate that these complications vary in their effect on outcome, and many are not necessarily life threatening on their own. Therefore, "severe," as defined by Atlanta, must be distinguished from "prognostic, aiming at nonsurvival. In the first week after disease onset, pancreatitis-related organ failure is the preferred variable for predicting severity and prognosis because it outweighs morphologic complications. Contrast-enhanced CT and MRI allow for accurate stratification of local severity beyond the first week after symptom onset. Among the biochemical markers, C-reactive protein is still the parameter of choice to assess attack severity, although prognostic estimation is not possible. Other markers, including pancreatic protease activation peptides, interleukins-6 and -8, and polymorphonuclear elastase are useful early indicators of severity. Procalcitonin is one of the most promising single markers for assessment of major complications and prognosis throughout the disease course. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：107 / 115

页数：8

共 65 条

[41] Appelros S., Petersson U., Toh S., Et al., Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of the severity of acute pancreatitis, Br J Surg, 88, pp. 216-221, (2001)
[42] Muller C.A., Appelros S., Uhl W., Et al., Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases, Gut, 51, pp. 229-235, (2002)
[43] Saez J., Martinez J., Trigo C., Et al., Comparative study of the activation peptide of carboxypeptidase B and trypsinogen as early predictors of the severity of acute pancreatitis, Pancreas, 29, (2004)
[44] Mayer J.M., Raraty M., Slavin J., Et al., Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis, Br J Surg, 89, pp. 163-171, (2002)
[45] Wilson C., Heads A., Shenkin A., Imrie C.W., C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis, Br J Surg, 76, pp. 177-181, (1989)
[46] Mentula P., Kylanpaa M.L., Kemppainen E., Et al., Early prediction of organ failure by combined markers in patients with acute pancreatitis, Br J Surg, 92, (2005)
[47] Rau B., Steinbach G., Baumgart K., Et al., Serum amyloid A versus C-reactive protein in acute pancreatitis: Clinical value of an alternative acute-phase reactant, Crit Care Med, 28, pp. 736-742, (2000)
[48] Mayer J., Rau B., Gansauge F., Beger H.G., Inflammatory mediators in human acute pancreatitis: Clinical and pathophysiological implications, Gut, 47, pp. 546-552, (2000)
[49] Brivet F.G., Emilie D., Galanaud P., Pro- and anti-inflammatory cytokines during acute severe pancreatitis: An early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis, Crit Care Med, 27, pp. 749-755, (1999)
[50] Chen C.C., Wang S.S., Lee F.Y., Et al., Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis, Am J Gastroenterol, 94, pp. 213-218, (1999)

← 1 2 3 4 5 6 7 →